BNP/NT-proBNP in pulmonary arterial hypertension: time for point-of-care testing?
Despite the advent of new therapies and improved outcomes in patients with pulmonary arterial hypertension (PAH), it remains a life-shortening disease and the time to diagnosis remains unchanged. Strategies to improve outcomes are therefore currently focused on earlier diagnosis and a treatment appr...
Main Authors: | Robert A. Lewis, Charlotte Durrington, Robin Condliffe, David G. Kiely |
---|---|
Format: | Article |
Language: | English |
Published: |
European Respiratory Society
2020-05-01
|
Series: | European Respiratory Review |
Online Access: | http://err.ersjournals.com/content/29/156/200009.full |
Similar Items
-
Sendaway capillary NT-proBNP in pulmonary hypertension
by: Eleanor Morris, et al.
Published: (2024-07-01) -
The integration of BNP and NT-proBNP into clinical medicine
by: Swiss Medical Weekly
Published: (2007-01-01) -
Urinary NT-proBNP compared head-to-head to plasmatic NT-proBNP in a real life collective with an ICD
by: Benedikt Seither, et al.
Published: (2024-11-01) -
Towards Point-of-Care Heart Failure Diagnostic Platforms: BNP and NT-proBNP Biosensors
by: Hussein Alawieh, et al.
Published: (2019-11-01) -
Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure
by: A Palazzuoli, et al.
Published: (2010-05-01)